AccuraDX Inc.

ACCURADX

Downloadable computer software that is focusing on bioinformatics analyses of NGS data for research use only and/or medical?diagnostic purposes via laboratory-developed tests (LDTs) and FDA-approved in vitro diagnostics (IVDs);genetics, genomics and epigenomics-related reagents for medical diagnostic purposes via laboratory-developed tests (LDTs) and FDA-approved in vitro diagnostics (IVDs);ACURA DX;genetics, genomics and epigenomics-related reagents for research use, including for nucleic acid and protein sample preparation for next-generation sequencing (NGS);Research, analytical and consulting services that focus on next-generation sequencing (NGS) and sample preparation therefor,?performance for NGS, and services regarding DNA and RNA mapping technologies including KAS-seq, Keth-seq, CAP-C, and?services assisting researchers using of NGS technologies; research, analytical and consulting services for medical diagnostic?purposes via laboratory-developed tests (LDTs) and FDA-approved in vitro diagnostics (IVDs); software as a service (SAAS) services analytic platform focusing on bioinformatics analyses of NGS data for research use only and/or and future medical diagnostic purposes via laboratory-developed tests (LDTs) and FDA-?approved in vitro diagnostics (IVDs);

ACCURADX

The mark consists of the wording ACCURADX with a DNA symbol partially circling the letters DX.;Downloadable computer software that is focusing on bioinformatics analyses of NGS data for research use only and/or medical?diagnostic purposes via laboratory-developed tests (LDTs) and FDA-approved in vitro diagnostics (IVDs);genetics, genomics and epigenomics-related reagents for medical diagnostic purposes via laboratory-developed tests (LDTs) and FDA-approved in vitro diagnostics (IVDs);genetics, genomics and epigenomics-related reagents for research use, including for nucleic acid and protein sample preparation for next-generation sequencing (NGS);Research, analytical and consulting services that focus on next-generation sequencing (NGS) and sample preparation therefor,?performance for NGS, and services regarding DNA and RNA mapping technologies including KAS-seq, Keth-seq, CAP-C, and?services assisting researchers using of NGS technologies; research, analytical and consulting services for medical diagnostic?purposes via laboratory-developed tests (LDTs) and FDA-approved in vitro diagnostics (IVDs); software as a service (SAAS) services analytic platform focusing on bioinformatics analyses of NGS data for research use only and/or and future medical diagnostic purposes via laboratory-developed tests (LDTs) and FDA-?approved in vitro diagnostics (IVDs);